Join Growin Stock Community!

Ocular therapeutix, inc.OCUL.US Overview

US StockHealthcare
(No presentation for OCUL)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

OCUL AI Insights

OCUL Overall Performance

OCUL AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

OCUL Recent Performance

10.62%

Ocular therapeutix, inc.

0.05%

Avg of Sector

-0.31%

S&P500

OCUL PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

OCUL Key Information

OCUL Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

OCUL Profile

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant that is in phase 1 clinical trials for the treatment of wet age-related macular degeneration and other retinal diseases; OTX-TIC, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of dry age-related macular degeneration (dMAD). Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

Price of OCUL

OCUL FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

OCUL Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.22
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
37.46
PB Ratio
3.19
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
87.35%
Net Margin
-511.90%
Revenue Growth (YoY)
-18.47%
Profit Growth (YoY)
-21.89%
3-Year Revenue Growth
-1.99%
3-Year Profit Growth
-3.73%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.22
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
37.46
PB Ratio
3.19
Price-to-FCF
-
Gross Margin
87.35%
Net Margin
-511.90%
Revenue Growth (YoY)
-18.47%
Profit Growth (YoY)
-21.89%
3-Year Revenue Growth
-1.99%
3-Year Profit Growth
-3.73%

  • When is OCUL's latest earnings report released?

    The most recent financial report for Ocular therapeutix, inc. (OCUL) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating OCUL's short-term business performance and financial health. For the latest updates on OCUL's earnings releases, visit this page regularly.

  • What is the operating profit of OCUL?

    According to the latest financial report, Ocular therapeutix, inc. (OCUL) reported an Operating Profit of -69.76M with an Operating Margin of -526.49% this period, representing a decline of 37.93% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is OCUL's revenue growth?

    In the latest financial report, Ocular therapeutix, inc. (OCUL) announced revenue of 13.25M, with a Year-Over-Year growth rate of -22.43%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does OCUL have?

    As of the end of the reporting period, Ocular therapeutix, inc. (OCUL) had total debt of 76.97M, with a debt ratio of 0.1. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does OCUL have?

    At the end of the period, Ocular therapeutix, inc. (OCUL) held Total Cash and Cash Equivalents of 738.67M, accounting for 0.91 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does OCUL go with three margins increasing?

    In the latest report, Ocular therapeutix, inc. (OCUL) did not achieve the “three margins increasing” benchmark, with a gross margin of 88%%, operating margin of -526.49%%, and net margin of -488%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess OCUL's profit trajectory and future growth potential.

  • Is OCUL's EPS continuing to grow?

    According to the past four quarterly reports, Ocular therapeutix, inc. (OCUL)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.27. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of OCUL?

    Ocular therapeutix, inc. (OCUL)'s Free Cash Flow (FCF) for the period is -57.09M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 44.05% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of OCUL?

    The latest valuation data shows Ocular therapeutix, inc. (OCUL) has a Price-To-Earnings (PE) ratio of -7.29 and a Price/Earnings-To-Growth (PEG) ratio of 0.44. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.